ADC Therapeutics SA (ADCT) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Phibro Animal Health (PAHC) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 3.0% versus a loss of 62.3%. Over five years, PAHC leads with a +75.7% price change compared with -93.2% for ADCT. Phibro Animal Health is the larger company by market cap ($1.56 billion vs $220.9 million), about 7.0 times the size.
Phibro Animal Health pays a dividend yielding 1.25%, while ADC Therapeutics SA does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | PAHC |
|---|---|---|
| Share price | $1.73 | $38.30 |
| Market cap | $220.87M | $1.56B |
| 1-day change | +8.81% | +2.41% |
| YTD return | -50.99% | +2.52% |
| 1-year return | -62.31% | +3.04% |
| 5-year return | -93.21% | +75.69% |
| P/E ratio (TTM) | — | 15.76 |
| Forward P/E | — | 9.97 |
| EPS (TTM) | $-0.60 | $2.43 |
| Dividend yield | 0.00% | 1.25% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | — | $1.52B |
| Revenue growth (YoY) | — | +17.12% |
| Net income (latest FY) | — | $99.72M |
| Gross margin | — | 33.76% |
| Operating margin | — | 12.81% |
| Net margin | — | 6.57% |
| 52-week high | $4.98 | $60.08 |
| 52-week low | $0.78 | $28.25 |
| Distance from 52-week high | -65.26% | -36.25% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +92.49% | +14.88% |
| Average volume | 1.45M | 231.66K |
| Shares outstanding | 127.67M | 21.11M |
| Employees | 188 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Phibro Animal Health is about 7.0 times larger than ADC Therapeutics SA by market value ($1.56B vs $220.87M).
- PAHC has outperformed ADCT by 65.3 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.25% vs 0.00%).
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
ADCT vs PAHC FAQ
Which is bigger, ADC Therapeutics SA or Phibro Animal Health?
Phibro Animal Health (PAHC) is larger, with a market capitalization of $1.56B compared with $220.87M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or PAHC?
PAHC returned +3.04% over the past 12 months, compared with -62.31% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, ADC Therapeutics SA or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.25%, while ADC Therapeutics SA does not currently pay a regular dividend.
Are ADC Therapeutics SA and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.